GlassScriptPhysician profile
Barry Rubino
NPI 1568541027
$2,827.49
in general payments reported to CMS, 2019-2025
22 companies · $171 in 2025
The $171 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $377 · 2020: $110 · 2021: $895 · 2022: $655 · 2023: $345 · 2024: $274 · 2025: $171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $790.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $790.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $648.09 | 2021-2025 | Qulipta, Vraylar, Ubrelvy |
| Novo Nordisk INC | $539.79 | 2019-2023 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $337.92 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $299.13 | 2019-2025 | Trintellix |
| Biohaven Pharmaceutical Holding Company LTD. | $214.62 | 2022 | |
| Amgen INC. | $203.73 | 2022-2025 | Krystexxa |
| Biohaven Pharmaceuticals, INC. | $154.71 | 2021 | |
| Arbor Pharmaceuticals, INC. | $71.48 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $63.55 | 2019-2022 | |
| Inspire Medical Systems, INC. | $60.82 | 2024 | Inspire |
| Kowa Pharmaceuticals America, INC. | $42.29 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.79 | 2025 | |
| Glaxosmithkline, LLC. | $26.15 | 2021 | |
| Allergan, INC. | $24.13 | 2020 | |
| Janssen Pharmaceuticals, INC | $15.53 | 2023 | Xarelto |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $15.39 | 2022 | |
| Lundbeck LLC | $15.36 | 2025 | Rexulti |
| Genentech USA, INC. | $14.87 | 2020 | |
| Amarin Pharma, INC. | $14.61 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $13.22 | 2023 | Rexulti |
| Horizon Therapeutics Plc | $12.47 | 2022 | |
| Avanir Pharmaceuticals, INC. | $10.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Rubino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.